Clinical study on the prevalence and comparative analysis of metabolic syndrome and its components among Chinese breast cancer women and control population

Abstract

Metabolic syndrome has been previously identified as a risk factor for breast cancer and is increasingly a public health concern. This study aims to investigate the prevalence of metabolic syndrome and its components among primary breast cancer and control population. The clinical data of metabolic syndrome and its components in the breast cancer (605 cases) and control population (3212 cases), from Breast Cancer Center and Physical Examination Center of Chongqing, China, from July 2015 to February 2017, were collected for comparative analysis. This study was prospectively registered in Chinese Clinical Trial Registry (http://www.chictr.org.cn/, number: ChiCTR-OOB-15007543). The prevalence of metabolic syndrome in breast cancer (32.6%) was obviously higher than that in control population (18.2%) (p<0.001; OR: 2.173, 95%CI: 1.793 to 2.633). With age stratification, the prevalence of metabolic syndrome in breast cancer group aged below 60 years (24.9%, p<0.001; OR: 2.216, 95%CI: 1.744 to 2.816) and equal/above 60 years (58.3%, p<0.001; OR: 2.291, 95%CI: 1.580 to 3.322) were also statistically higher than those (13.0% & 37.9%) in control population, respectively. Breast cancer women were more likely to have preobese (BMI 25.0-29.9) or obesity (BMI ≥30.0), broader waist circumference, lower HDL-C level, higher systolic and/or diastolic blood pressure and higher fasting blood glucose level compared to the control population, corresponding prevalence were 31.7%vs.19.4%, 76.0%vs.29.6%, 37.4%vs.30.4%, 34.2%/27.3%vs.27.6%/14.2% and 25.0%vs.20.1%, respectively (p<0.01). In summary, there is high prevalence of metabolic syndrome and its components in Chinese breast cancer women, and metabolic syndrome is closely related with breast cancer. Therefore, screening and prevention strategy of metabolic syndrome should be carried out in the management of breast cancer.

Assessment of the awareness and knowledge of cancer survivors regarding the components of metabolic syndrome

“…In this study, the prevalence of MetS among cancer survivors was 34.1% which is consistent with the findings of a previous study [ 19 ]. However, there were significant differences in the reported prevalence of MetS among cancer patients in another previous study [ 20 ], which reported the differences in the prevalence of MetS among women with breast cancer according to tumor stage.…”

Prevalence of Metabolic Syndrome among Breast Cancer Survivors in East Coast of Peninsular Malaysia

“…This difference can be attributed to the variation in breast cancer survival duration and ethnic composition percentage among the breast cancer survivors between these two studies. Furthermore, MetS prevalence among breast cancer survivors as reported in the current study was also similar, or higher than the data reported in other countries such as India -NCEP ATP III definition: 40.0% vs 40.0% respectively (Wani et al 2017), China -Harmonized definition: 50.5% vs 32.6% (Wu et al 2018), Korea -Harmonized definition: 50.5% vs 43.9% (Lee et al 2013), USA -Harmonized: 50.5% vs 26.1% (Calip et al 2014), Denmark -NCEP ATP III definition:…”

“…Similar to the findings of previous research, this study reported significant links between MetS and increased body weight (Ching et al 2018;Moreira et al 2014;Ortiz-Rodríguez et al 2017), waist circumference (Johari and Shahar 2014;Ortiz-Rodríguez et al 2017;Raposo et al 2017), body fat percentage (Johari and Shahar 2014;Ortiz-Rodríguez et al 2017) and BMI (Wu et al 2018). However, we did not find a significant difference across MetS status in any specific sociodemographic profile, total cholesterol level or LDL-c level.…”

“…In this study conducted among 370 newly diagnosed breast cancer patients recruited from University Malaya Medical Centre (UMMC), the prevalence of MetS was reported to be 37.8%, using the modified IDF 2005 definition (Kiew et al 2018). In comparison to MetS prevalence among breast cancer survivors in other Asian countries, the prevalence of MetS in India were reported to range between 32.1% (Kate and Kadambari 2016) and 40.0% (Wani et al 2017), whereas MetS prevalence in China and Korea were 32.6% (Wu et al 2018) and 43.9% (Lee et al 2013) respectively. Meanwhile, studies conducted in the USA, Denmark and Brazil reported Mets prevalence among breast cancer survivors to be 26.1% (Calip et al 2014), 15.1% (Fredslund et al 2019), and 48.1% (Nahas et al 2012) respectively.…”

The Metabolic Syndrome Is a Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis

“…(2) TG ≥150 mg/dL and/or HDL-C < 40 mg/dL and/or the use of antihyperlipidemic medication; (3) fasting blood glucose ≥110 mg/dL (with a fasting duration of ≥3 h), or casual blood glucose (for < 3 h or without regard to the time since the last meal) ≥140 mg/dL and/or the use of antidiabetic medication. In some Chinese studies, experts defined the cutoff of waist circumference as 80 cm for females [17]. Forest plot assessing the risk of breast cancer incidence associated with the metabolic syndrome according to the study type (cohort study or case-control study).…”